In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
October 27th, 2004 | 28 | Yes |
Popular Name: LckInhibitor LckInhibitor
Find On: PubMed — Wikipedia — Google
CAS Number: 213743-31-8
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 5.10 | 13.4 | -8.75 | 2 | 5 | 0 | 66 | 370.456 | 4 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
PUBCHEM_PATENT_ID | WO2000017203A1 | IBM Patent Data |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
BLK-1-E | Tyrosine-protein Kinase BLK (cluster #1 Of 1), Eukaryotic | Eukaryotes | 66 | 0.36 | Binding ≤ 10μM |
CSK-1-E | Tyrosine-protein Kinase CSK (cluster #1 Of 1), Eukaryotic | Eukaryotes | 5180 | 0.26 | Binding ≤ 10μM |
EGFR-1-E | Epidermal Growth Factor Receptor ErbB1 (cluster #1 Of 4), Eukaryotic | Eukaryotes | 3200 | 0.27 | Binding ≤ 10μM |
FYN-1-E | Tyrosine-protein Kinase FYN (cluster #1 Of 5), Eukaryotic | Eukaryotes | 126 | 0.34 | Binding ≤ 10μM |
LCK-1-E | Tyrosine-protein Kinase LCK (cluster #1 Of 4), Eukaryotic | Eukaryotes | 16 | 0.39 | Binding ≤ 10μM |
LYN-1-E | Tyrosine-protein Kinase Lyn (cluster #1 Of 1), Eukaryotic | Eukaryotes | 420 | 0.32 | Binding ≤ 10μM |
SRC-1-E | Tyrosine-protein Kinase SRC (cluster #1 Of 3), Eukaryotic | Eukaryotes | 70 | 0.36 | Binding ≤ 10μM |
TIE2-1-E | Tyrosine-protein Kinase TIE-2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 9070 | 0.25 | Binding ≤ 10μM |
VGFR2-1-E | Vascular Endothelial Growth Factor Receptor 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 4440 | 0.27 | Binding ≤ 10μM |
Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 3162 | 0.28 | Functional ≤ 10μM |
Z81072-1-O | Jurkat (Acute Leukemic T-cells) (cluster #1 Of 10), Other | Other | 800 | 0.30 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
BLK_HUMAN | P51451 | Tyrosine-protein Kinase BLK, Human | 66 | 0.36 | Binding ≤ 1μM |
BLK_MOUSE | P16277 | Tyrosine-protein Kinase BLK, Mouse | 66 | 0.36 | Binding ≤ 1μM |
FYN_HUMAN | P06241 | Tyrosine-protein Kinase FYN, Human | 126 | 0.34 | Binding ≤ 1μM |
LCK_MOUSE | P06240 | Tyrosine-protein Kinase LCK, Mouse | 16 | 0.39 | Binding ≤ 1μM |
LCK_HUMAN | P06239 | Tyrosine-protein Kinase LCK, Human | 1 | 0.45 | Binding ≤ 1μM |
LYN_HUMAN | P07948 | Tyrosine-protein Kinase Lyn, Human | 420 | 0.32 | Binding ≤ 1μM |
SRC_HUMAN | P12931 | Tyrosine-protein Kinase SRC, Human | 560 | 0.31 | Binding ≤ 1μM |
EGFR_HUMAN | P00533 | Epidermal Growth Factor Receptor ErbB1, Human | 3200 | 0.27 | Binding ≤ 10μM |
BLK_MOUSE | P16277 | Tyrosine-protein Kinase BLK, Mouse | 66 | 0.36 | Binding ≤ 10μM |
BLK_HUMAN | P51451 | Tyrosine-protein Kinase BLK, Human | 66 | 0.36 | Binding ≤ 10μM |
CSK_HUMAN | P41240 | Tyrosine-protein Kinase CSK, Human | 5180 | 0.26 | Binding ≤ 10μM |
FYN_HUMAN | P06241 | Tyrosine-protein Kinase FYN, Human | 126 | 0.34 | Binding ≤ 10μM |
LCK_MOUSE | P06240 | Tyrosine-protein Kinase LCK, Mouse | 1070 | 0.30 | Binding ≤ 10μM |
LCK_HUMAN | P06239 | Tyrosine-protein Kinase LCK, Human | 1 | 0.45 | Binding ≤ 10μM |
LYN_HUMAN | P07948 | Tyrosine-protein Kinase Lyn, Human | 420 | 0.32 | Binding ≤ 10μM |
SRC_HUMAN | P12931 | Tyrosine-protein Kinase SRC, Human | 560 | 0.31 | Binding ≤ 10μM |
TIE2_HUMAN | Q02763 | Tyrosine-protein Kinase TIE-2, Human | 1980 | 0.29 | Binding ≤ 10μM |
VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 1570 | 0.29 | Binding ≤ 10μM |
Z81072 | Z81072 | Jurkat (Acute Leukemic T-cells) | 1500 | 0.29 | Functional ≤ 10μM |
Z50425 | Z50425 | Plasmodium Falciparum | 2511.88643 | 0.28 | Functional ≤ 10μM |
Description | Species |
---|---|
Antigen activates B Cell Receptor (BCR) leading to generation of second messenge | |
CD28 co-stimulation | |
CD28 dependent PI3K/Akt signaling | |
CD28 dependent Vav1 pathway | |
Cell surface interactions at the vascular wall | |
Constitutive PI3K/AKT Signaling in Cancer | |
CRMPs in Sema3A signaling | |
CTLA4 inhibitory signaling | |
DAP12 signaling | |
DCC mediated attractive signaling | |
Downstream TCR signaling | |
EGFR downregulation | |
EGFR interacts with phospholipase C-gamma | |
EGFR Transactivation by Gastrin | |
EPH-ephrin mediated repulsion of cells | |
EPH-Ephrin signaling | |
EPHA-mediated growth cone collapse | |
EPHB-mediated forward signaling | |
Ephrin signaling | |
Fc epsilon receptor (FCERI) signaling | |
FCERI mediated Ca+2 mobilization | |
FCERI mediated MAPK activation | |
FCERI mediated NF-kB activation | |
FCGR activation | |
GAB1 signalosome | |
Generation of second messenger molecules | |
GPVI-mediated activation cascade | |
GRB2 events in EGFR signaling | |
GRB2 events in ERBB2 signaling | |
Growth hormone receptor signaling | |
Integrin alphaIIb beta3 signaling | |
Integrin cell surface interactions | |
Interleukin-2 signaling | |
NCAM signaling for neurite out-growth | |
Nef and signal transduction | |
Nef Mediated CD4 Down-regulation | |
Nephrin interactions | |
Netrin mediated repulsion signals | |
Neurophilin interactions with VEGF and VEGFR | |
PD-1 signaling | |
PECAM1 interactions | |
Phosphorylation of CD3 and TCR zeta chains | |
PI3K events in ERBB2 signaling | |
PIP3 activates AKT signaling | |
Platelet Adhesion to exposed collagen | |
PLCG1 events in ERBB2 signaling | |
Regulation of KIT signaling | |
Regulation of signaling by CBL | |
Role of LAT2/NTAL/LAB on calcium mobilization | |
Sema3A PAK dependent Axon repulsion | |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | |
SHC1 events in EGFR signaling | |
SHC1 events in ERBB2 signaling | |
Signal transduction by L1 | |
Signaling by constitutively active EGFR | |
Signaling by EGFR | |
Signaling by ERBB2 | |
Signaling by ERBB4 | |
Signaling by SCF-KIT | |
Tie2 Signaling | |
Translocation of ZAP-70 to Immunological synapse | |
VEGF binds to VEGFR leading to receptor dimerization | |
VEGFA-VEGFR2 Pathway | |
VEGFR2 mediated cell proliferation |
No pre-computed analogs available. Try a structural similarity search.